Activity of short lipopeptides and conventional antimicrobials against planktonic cells and biofilms formed by clinical strains of Staphylococcus aureus.

BACKGROUND The therapy for staphylococcal skin diseases is facing several difficulties caused by the growth of biofilms and development of resistant strains. Short synthetic lipopeptides designed on the basis of antimicrobial peptide structure seem to provide an alternative to conventional therapy. The purpose of this study was to synthesize a group of lipopeptides and evaluate their antistaphylococcal activity against biofilms formed by clinical strains of Staphylococcus aureus. RESULTS The compounds exhibited a strong antibiofilm activity against all the isolates. The maturity of the biofilms has shown a well-defined influence on antimicrobial activity of conventional antimicrobials. DISCUSSION Results showed that the lipopeptides were promising agents as the time of the culture did not greatly affect their activity.

[1]  S. Kaplan,et al.  Mupirocin Resistance in Staphylococcus aureus Causing Recurrent Skin and Soft Tissue Infections in Children , 2011, Antimicrobial Agents and Chemotherapy.

[2]  R. Dellavalle,et al.  Infectious skin diseases: a review and needs assessment. , 2012, Dermatologic clinics.

[3]  L. Eron.  Cellulitis and Soft-Tissue Infections , 2009, Annals of Internal Medicine.

[4]  I. Gould,et al.  Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? , 2011, International journal of antimicrobial agents.

[5]  Roberto Kolter,et al.  Extracellular signaling and multicellularity in Bacillus subtilis. , 2011, Current opinion in microbiology.

[6]  W. Kamysz,et al.  The lipopeptides Pal–Lys–Lys–NH2 and Pal–Lys–Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection , 2007, Peptides.

[7]  J. Łukasiak,et al.  Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. , 2007, JPEN. Journal of parenteral and enteral nutrition.

[8]  A. Beauvais,et al.  Efficient Clearance of Aspergillus fumigatus in Murine Lungs by an Ultrashort Antimicrobial Lipopeptide, Palmitoyl-Lys-Ala-dAla-Lys , 2008, Antimicrobial Agents and Chemotherapy.

[9]  M. Okrój,et al.  In Vitro Activities of the Lipopeptides Palmitoyl (Pal)-Lys-Lys-NH2 and Pal-Lys-Lys Alone and in Combination with Antimicrobial Agents against Multiresistant Gram-Positive Cocci , 2006, Antimicrobial Agents and Chemotherapy.

[10]  Tyring Sk,et al.  Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? , 2010 .

[11]  Tom Coenye,et al.  In vitro and in vivo model systems to study microbial biofilm formation. , 2010, Journal of microbiological methods.

[12]  Y. Shai,et al.  Inhibition of Fungal and Bacterial Plant Pathogens In Vitro and In Planta with Ultrashort Cationic Lipopeptides , 2007, Applied and Environmental Microbiology.

[13]  W. Kamysz,et al.  In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients. , 2005, International journal of antimicrobial agents.

[14]  J. Perkins,et al.  Skin and soft tissue infections. , 2006, Primary care.

[15]  Paul Stoodley,et al.  Evolving concepts in biofilm infections , 2009, Cellular microbiology.

[16]  K. Leung,et al.  The effect of lactoferrin on oral bacterial attachment. , 2009, Oral microbiology and immunology.

[17]  P. Schlievert,et al.  Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. , 2010, The Journal of allergy and clinical immunology.

[18]  H. Kalbacher,et al.  Susceptibility of clinical Staphylococcus aureus isolates to innate defense antimicrobial peptides. , 2011, Microbes and infection.

[19]  N. Kumar,et al.  A novel cationic‐peptide coating for the prevention of microbial colonization on contact lenses , 2008, Journal of applied microbiology.

[20]  C. Padilla,et al.  In vitro antimicrobial effect of bacteriocin PsVP-10 in combination with chlorhexidine and triclosan against Streptococcus mutans and Streptococcus sobrinus strains. , 2009, Archives of oral biology.

[21]  G. Lina,et al.  New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. , 2013, International journal of antimicrobial agents.

[22]  M. Yoshinari,et al.  Prevention of biofilm formation on titanium surfaces modified with conjugated molecules comprised of antimicrobial and titanium-binding peptides , 2010, Biofouling.

[23]  Ronald N. Jones,et al.  Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008 , 2010, Antimicrobial Agents and Chemotherapy.

[24]  R. Hancock,et al.  Human Host Defense Peptide LL-37 Prevents Bacterial Biofilm Formation , 2008, Infection and Immunity.

[25]  U. Römling,et al.  Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis , 2010, Letters in applied microbiology.

[26]  G. Gherardi,et al.  Macrolide resistance genotypes and phenotypes among erythromycin-resistant clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci, Italy. , 2009, FEMS immunology and medical microbiology.

[27]  R. Eckert.  Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. , 2011, Future microbiology.

[28]  Wojciech Kamysz,et al.  In Vitro Activity of Aurein 1.2 Alone and in Combination with Antibiotics against Gram-Positive Nosocomial Cocci , 2007, Antimicrobial Agents and Chemotherapy.

[29]  B. Howden,et al.  Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  M. Provinciali,et al.  Lipopeptide Laur-CKK-NH2 dimer preserves daptomycin susceptibility and enhances its activity against Enterococcus faecalis. , 2011, The Journal of antimicrobial chemotherapy.

[31]  D. Davidson,et al.  Impact of LL‐37 on anti‐infective immunity , 2005, Journal of leukocyte biology.

[32]  W. Kamysz,et al.  Colorimetric evaluation of the time-killing assay for Citropin 1.1, lipopeptide Palm-KK-NH2, and Temporin A. , 2011, Journal of microbiology and biotechnology.

[33]  S. Basak,et al.  Inducible Clindamycin Resistance in Staphylococcus Aureus-A Therapeutic Challenge , 2009 .

[34]  D. Elston.  Update on Cutaneous Manifestations of Infectious Diseases , 2009, The Medical clinics of North America.

[35]  S. Monecke,et al.  Detection of Staphylococcal Cassette Chromosome mec Type XI Carrying Highly Divergent mecA, mecI, mecR1, blaZ, and ccr Genes in Human Clinical Isolates of Clonal Complex 130 Methicillin-Resistant Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[36]  J. Łukasiak,et al.  Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection , 2006, Peptides.

[37]  M. Robbins,et al.  Investigation of the Potential for Mutational Resistance to XF-73, Retapamulin, Mupirocin, Fusidic Acid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus Isolates during a 55-Passage Study , 2010, Antimicrobial Agents and Chemotherapy.

[38]  K. Lewis.  Multidrug tolerance of biofilms and persister cells. , 2008, Current topics in microbiology and immunology.

[39]  R. Egleton,et al.  Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.

[40]  David W Williams,et al.  Microbiology of the skin and the role of biofilms in infection , 2012, International wound journal.

[41]  A. van Belkum,et al.  Effect of Mupirocin Treatment on Nasal, Pharyngeal, and Perineal Carriage of Staphylococcus aureus in Healthy Adults , 2005, Antimicrobial Agents and Chemotherapy.

[42]  A. Baccarelli,et al.  Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial , 2008, Intensive Care Medicine.

[43]  V. Plakunov,et al.  Biofilm—“City of microbes” or an analogue of multicellular organisms? , 2007, Microbiology.

[44]  A. Mankin,et al.  Erythromycin- and Chloramphenicol-Induced Ribosomal Assembly Defects Are Secondary Effects of Protein Synthesis Inhibition , 2008, Antimicrobial Agents and Chemotherapy.

[45]  W. Kamysz,et al.  In Vitro Activity and Killing Effect of Uperin 3.6 against Gram-Positive Cocci Isolated from Immunocompromised Patients , 2005, Antimicrobial Agents and Chemotherapy.

[46]  Valerie Nguyen,et al.  Evidence for persisters in Staphylococcus epidermidis RP62a planktonic cultures and biofilms. , 2011, Journal of medical microbiology.

[47]  M. Möller,et al.  Surface Coating Strategies to Prevent Biofilm Formation on Implant Surfaces , 2010 .

[48]  Robin Patel,et al.  Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections. , 2012, Infectious disease clinics of North America.

[49]  K. Lewis.  Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[50]  Y. Shai,et al.  Ultrashort antibacterial and antifungal lipopeptides , 2006, Proceedings of the National Academy of Sciences.

[51]  Eve Neesham-Grenon,et al.  Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[52]  W. Kamysz,et al.  The antimicrobial peptide Tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model , 2007, Peptides.

[53]  W. Kamysz,et al.  In vitro activity of the lipopeptide derivative (Pal‐lys‐lys‐NH2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes , 2009, The British journal of dermatology.

[54]  R. Darouiche,et al.  Role of Antibiofilm-Antimicrobial Agents in Controlling Device-Related Infections , 2011, The International journal of artificial organs.

[55]  G. Robertson,et al.  Bacterial and fungal biofilm infections. , 2008, Annual review of medicine.

[56]  A. Pantosti,et al.  Mechanisms of antibiotic resistance in Staphylococcus aureus. , 2007, Future microbiology.

[57]  Takashi Oono,et al.  Staphylococcal cutaneous infections: invasion, evasion and aggression. , 2006, Journal of dermatological science.

[58]  J. Łukasiak,et al.  In Vitro Activity of the Histatin Derivative P-113 against Multidrug-Resistant Pathogens Responsible for Pneumonia in Immunocompromised Patients , 2005, Antimicrobial Agents and Chemotherapy.

[59]  W. Kamysz,et al.  In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. , 2009, Medical mycology.

[60]  Wojciech Kamysz,et al.  In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH2 alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans , 2007, Peptides.

[61]  D. Stevens.  Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. , 2009, The Journal of infection.

[62]  A. Schmidtchen,et al.  In Silico Identification and Biological Evaluation of Antimicrobial Peptides Based on Human Cathelicidin LL-37 , 2006, Antimicrobial Agents and Chemotherapy.

[63]  M Cristina L Martins,et al.  Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. , 2011, Acta biomaterialia.